Patent application number | Description | Published |
20090160106 | APPARATUS AND METHOD FOR SIMULTANEOUS USAGE OF MULTIPLE DIE CASTING TOOLS - The preferred embodiment of the present invention is a die casting apparatus and method evidencing increased apparatus output including the ability of using multiple die tools. The invention includes an indexing assembly removably engaged with at least one die block assembly for transporting between four stations, including an injection station, a cooling station, an ejection station, and a recovery station. The injection station includes a frame, a clamp assembly attached to the frame for clamping and releasing the die block assembly, a shot sleeve assembly engaged with the die block assembly for receiving molten material, such as metal, from a furnace means and injecting the molten material into the die block assembly, and a shot cylinder releasably coupled with the shot sleeve assembly for controlling the injection of molten material. The ejection station includes an ejector lift assembly which engages the die block assembly for ejecting a finished part from the die block assembly, and the recovery station includes an ejector drop assembly which engages the die block assembly for placing a preload on the die block assembly. | 06-25-2009 |
20110017420 | APPARATUS AND METHOD FOR SIMULTANEOUS USAGE OF MULTIPLE DIE CASTING TOOLS - A die casting apparatus and method evidencing increased apparatus output including the ability of using multiple die tools. The apparatus includes an indexing assembly removably engaged with at least one die block assembly for transporting between four stations, including an injection station, a cooling station, an ejection station, and a recovery station. The injection station includes a frame, a clamp assembly attached to the frame for clamping and releasing the die block assembly, a shot sleeve assembly engaged with the die block assembly for receiving molten material, such as metal, from a furnace means and injecting the molten material into the die block assembly, and a shot cylinder releasably coupled with the shot sleeve assembly for controlling the injection of molten material. The ejection station includes an ejector lift assembly which engages the die block assembly for ejecting a finished part from the die block assembly, and the recovery station includes an ejector drop assembly which engages the die block assembly for placing a preload on the die block assembly. | 01-27-2011 |
Patent application number | Description | Published |
20080269262 | Therameutin Modulators - This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein. | 10-30-2008 |
20090275070 | Compounds and Methods of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators - This invention relates to methods of identifying, synthesizing, optimizing and profiling compounds that are inhibitors or activators of proteins, both naturally occurring endogenous proteins as well as certain variant forms of endogenous proteins, and novel methods of identifying such variants. The method accelerates the identification and development of compounds as potential therapeutically effective drugs by simplifying the pharmaceutical discovery and creation process through improvements in hit identification, lead optimization, biological profiling, and rapid elimination of toxic compounds. Implementation results in overall cost, reductions in the drug discovery process resulting from the corresponding increases in efficiency. | 11-05-2009 |
20130150358 | THERAMUTEIN MODULATORS - This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein. | 06-13-2013 |
20140120567 | Compounds and Method of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators - This invention relates to methods of identifying, synthesizing, optimizing and profiling compounds that are inhibitors or activators of proteins, both naturally occurring endogenous proteins as well as certain variant forms of endogenous proteins, and novel methods of identifying such variants. The method accelerates the identification and development of compounds as potential therapeutically effective drugs by simplifying the pharmaceutical discovery and creation process through improvements in hit identification, lead optimization, biological profiling, and rapid elimination of toxic compounds. Implementation results in overall cost reductions in the drug discovery process resulting from the corresponding increases in efficiency. | 05-01-2014 |
20140243398 | IRS MODULATORS - This invention is directed to a general method for the chronic treatment, potential cure, or prevention of various metabolic and related diseases in people, including diabetes, by modulating IRS2 activity in cells and tissues in the body. IRS1 and IRS2 are part of the insulin or insulin-like growth factor signaling pathway. By upregulating the levels or functional activity of IRS2, insulin is used more efficiently by the body to control nutrient levels. By upregulating IRS2 levels or functional activity in pancreatic β-cells, glucose sensing and insulin secretion are enhanced. | 08-28-2014 |
Patent application number | Description | Published |
20090158964 | Injectable calcium phosphate cement - The invention is related to a premixed putty calcium phosphate composition comprising at least two calcium phosphate minerals, at least one reaction retarding agent, at least one binding agent, at least one sodium phosphate, and at least one nonaqueous extender, wherein one of said at least two calcium phosphate minerals contains a stabilizing agent. | 06-25-2009 |
20090256285 | Method of producing a ceramic component - A method of producing a ceramic component includes dispersing an alpha-alumina nanopowder whose diameter is above 100 nm in water, using 2-phosphonobutane-1,2,4-tricarboxylic acid (PBTC) or 4,5-Dihydroxy-m-benzenedisulfonic Acid, Disodium Salt (Tiron™) as dispersant. The pH is shifted towards the isoelectric point (IEP) by adding a mixture of acetic anhydride and ethylene glycol or polyethylene glycol, drying in a controlled atmosphere (humidity, temperature) and post compacting using cold isostatic pressing and sintering the three-dimensional structure thus formed. | 10-15-2009 |
20100095870 | INJECTABLE CALCIUM PHOSPHATE CEMENT - The invention is related to a premixed putty calcium phosphate composition comprising at least two calcium phosphate minerals, at least one reaction retarding agent, at least one binding agent, at least one sodium phosphate, and at least one nonaqueous extender, wherein one of said at least two calcium phosphate minerals contains a stabilizing agent. | 04-22-2010 |
Patent application number | Description | Published |
20080213345 | Delivering Iron to an Animal - The invention provides a method for delivery iron to an animal. This invention further provides a method for treating iron deficiency in an animal. | 09-04-2008 |
20090060998 | LIPID-BASED DISPERSIONS USEFUL FOR DRUG DELIVERY - The invention provides lipid-based dispersion comprising, a) phosphatidyl choline; b) an anionic phospholipid; optionally c) up to 1% cholesterol by weight of total lipids; and optionally d) a therapeutic agent; wherein the mean particle size measured by dynamic light scattering is less than 100 nm. The invention also provides pharmaceutical compositions comprising such a dispersion as well as methods of producing a therapeutic effect in a mammal comprising administering an effective amount of such a dispersion. | 03-05-2009 |
20100119590 | Method of drug loading in liposomes by gradient - A method for encapsulation of pharmaceutical agents (e.g., antineoplastic agents) in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes can be made by a process that loads the drug by an active mechanism using a transmembrane pH gradient. Using this technique, trapping efficiencies approach 100%. Drug:lipid ratios employed are higher than for older traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. After loading, residual acid is quenched with a quenching agent that is base permeable at low temperatures. The residual aciditiy is thus reduced and chemical stability (e.g. against hydrolysis) is enhanced. The stability of both the liposome and the pharmaceutical agent is thus maintained, prior to administration. The pH gradient is, however, present when the liposome is administered in vivo because the quenching agent rapidly exits the liposome. | 05-13-2010 |
Patent application number | Description | Published |
20120177905 | NANOSTRUCTURED COMPOSITE REINFORCED MATERIAL - A family of materials wherein nanostructures and/or nanotubes are incorporated into a multi-component material arrangement, such as a metallic or ceramic alloy or composite/aggregate, producing a new material or metallic/ceramic alloy. The new material has significantly increased strength, up to several thousands of times normal and perhaps substantially more, as well as significantly decreased weight. The new materials may be manufactured into a component where the nanostructure or nanostructure reinforcement is incorporated into the bulk and/or matrix material, or as a coating where the nanostructure or nanostructure reinforcement is incorporated into the coating or surface of a “normal” substrate material. The nanostructures are incorporated into the material structure either randomly or aligned, within grains, or along or across grain boundaries. | 07-12-2012 |
20120324908 | APPARATUS AND METHOD FOR MAGNETICALLY PROCESSING A SPECIMEN - An apparatus for magnetically processing a specimen that couples high field strength magnetic fields with the magnetocaloric effect includes a high field strength magnet capable of generating a magnetic field of at least 1 Tesla and a magnetocaloric insert disposed within a bore of the high field strength magnet. A method for magnetically processing a specimen includes positioning a specimen adjacent to a magnetocaloric insert within a bore of a magnet and applying a high field strength magnetic field of at least 1 Tesla to the specimen and to the magnetocaloric insert. The temperature of the specimen changes during the application of the high field strength magnetic field due to the magnetocaloric effect. | 12-27-2012 |
20130014863 | METHOD OF MAGNETICALLY PROCESSING AN IRON-CARBON ALLOYAANM Ludtka; Gerard M.AACI Oak RidgeAAST TNAACO USAAGP Ludtka; Gerard M. Oak Ridge TN USAANM Ludtka; Gail M.AACI Oak RidgeAAST TNAACO USAAGP Ludtka; Gail M. Oak Ridge TN USAANM Wilgen; John B.AACI Oak RidgeAAST TNAACO USAAGP Wilgen; John B. Oak Ridge TN USAANM Kisner; Roger A.AACI KnoxvilleAAST TNAACO USAAGP Kisner; Roger A. Knoxville TN US - A magnetic field assisted processing method entails heating an iron-carbon alloy at an austenitizing temperature for a time duration sufficient for the alloy to achieve an austenitic microstructure; cooling the iron-carbon alloy to an intermediate temperature defined by a continuous cooling transformation (CCT) diagram for the iron-carbon alloy at a rate sufficient to avoid phase transformation of the austenitic microstructure, the intermediate temperature being below a bainitic knee of the CCT diagram and above a martensite start temperature; and applying a high field strength magnetic field of at least about 0.2 Tesla to the iron-carbon alloy after reaching the intermediate temperature. The field is applied for a time duration sufficient to transform the austenitic microstructure into a fine dispersion of one or more iron carbide phases in a ferrite matrix in order to produce a magnetically-processed alloy having improved ductility and strength. | 01-17-2013 |
20130089401 | Mitigated-Force Carriage for High Magnetic Field Environments - A carriage for high magnetic field environments includes a first work-piece holding means for holding a first work-piece, the first work-piece holding means being disposed in an operable relationship with a work-piece processing magnet having a magnetic field strength of at least 1 Tesla. The first work-piece holding means is further disposed in operable connection with a second work-piece holding means for holding a second work-piece so that, as the first work-piece is inserted into the magnetic field, the second work-piece is simultaneously withdrawn from the magnetic field, so that an attractive magnetic force imparted on the first work-piece offsets a resistive magnetic force imparted on the second work-piece. | 04-11-2013 |
20130119296 | Methods for Providing Surface Treatments in a Magnetic Field - The invention relates to methods for creating metal oxide coatings on one or more surfaces employing a magnetic field, and articles containing those coatings. Such methods involve contacting the surfaces to be treated with a metal compound, and converting the metal compound to metal oxide for example by heating the surfaces to the desired temperature in the presence of a magnetic field. The magnetic field dramatically improves, in some embodiments, the characteristics of the metal oxide coating. | 05-16-2013 |
20130146469 | Low Temperature Electrolytes for Solid Oxide Cells Having High Ionic Conductivity - Some embodiments of the present invention provide solid oxide cells and components thereof having a metal oxide electrolyte that exhibits enhanced ionic conductivity. Certain of those embodiments have two materials, at least one of which is a metal oxide, disposed so that at least some interfaces between the domains of the materials orient in a direction substantially parallel to the desired ionic conductivity. | 06-13-2013 |
20140020797 | MAGNETIC FIELD ANNEALING FOR IMPROVED CREEP RESISTANCE - The method provides heat-resistant chromia- or alumina-forming Fe-, Fe(Ni), Ni(Fe), or Ni-based alloys having improved creep resistance. A precursor is provided containing preselected constituents of a chromia- or alumina-forming Fe-, Fe(Ni), Ni(Fe), or Ni-based alloy, at least one of the constituents for forming a nanoscale precipitate MaXb where M is Cr, Nb, Ti, V, Zr, or Hf, individually and in combination, and X is C, N, O, B, individually and in combination, a=1 to 23 and b=1 to 6. The precursor is annealed at a temperature of 1000-1500° C. for 1-48 h in the presence of a magnetic field of at least 5 Tesla to enhance supersaturation of the M | 01-23-2014 |
20140110610 | Advanced Blow-out Preventer - An advanced blowout preventer that includes an arrester section and a shear section. The arrester section includes a number or arrester rings that are shaped to extend downwardly. The shape of the arrester rings allows the force of gas flowing out of the well to assist in closing the rings. The arrester section may have a number of arrester rings that cooperate to significantly reduce fluid from flowing in the annulus between a section of drill pipe and the blowout preventer. The advanced blowout preventer may also include a shear section. The shear section is configured to engage and shear a section of pipe using induction. | 04-24-2014 |
20140202833 | Mitigated-Force Carriage for High Magnetic Field Environments - A carriage for high magnetic field environments includes a plurality of work-piece separators disposed in an operable relationship with a work-piece processing magnet having a magnetic field strength of at least 1 Tesla for supporting and separating a plurality of work-pieces by a preselected, essentially equal spacing, so that, as a first work-piece is inserted into the magnetic field, a second work-piece is simultaneously withdrawn from the magnetic field, so that an attractive magnetic force imparted on the first work-piece offsets a resistive magnetic force imparted on the second work-piece. | 07-24-2014 |
Patent application number | Description | Published |
20150064077 | Method of Manufacturing Bio-Diesel and Reactor - A reactor and process for the production of bio-diesel. The reactor includes one or more coiled reaction lines. The lines are positioned within a tank containing a heat transfer media such as molten salt, maintained at about 750° F. A pump circulates the media within the tank. An emulsion of alcohol; refined feed stock, including glycerides and/or fatty acids; and preferably water is pumped through the reaction lines at temperatures and pressures sufficient to maintain the alcohol in a super-critical state. The curvature of the coils, pump pulsing, and the flow rate of the emulsion keep the emulsion in a turbulent state while in the reactor, ensuring thorough mixing of the alcohol and feed stock. The alcohol reacts with the glycerides and fatty acids to form bio-diesel. The reaction is fast, efficient with regard to energy input and waste generation, and requires minimal alcohol. | 03-05-2015 |
20150065745 | Method of Manufacturing Bio-Diesel and Reactor - A reactor and process for the production of bio-diesel. The reactor includes one or more coiled reaction lines. The lines are positioned within a tank containing a heat transfer media such as molten salt, maintained at about 750° F. A pump circulates the media within the tank. An emulsion of alcohol; refined feed stock, including glycerides and/or fatty acids; and preferably water is pumped through the reaction lines at temperatures and pressures sufficient to maintain the alcohol in a super-critical state. The curvature of the coils, pump pulsing, and the flow rate of the emulsion keep the emulsion in a turbulent state while in the reactor, ensuring thorough mixing of the alcohol and feed stock. The alcohol reacts with the glycerides and fatty acids to form bio-diesel. The reaction is fast, efficient with regard to energy input and waste generation, and requires minimal alcohol. | 03-05-2015 |
Patent application number | Description | Published |
20100196885 | METHODS OF VALIDATING CANDIDATE COMPOUNDS FOR USE IN TREATING COPD AND OTHER DISEASES - The present invention relates to methods of diagnosing and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease. | 08-05-2010 |
20130273586 | METHODS OF VALIDATING CANDIDATE COMPOUNDS FOR USE IN TREATING COPD AND OTHER DISEASES - The present invention relates to methods of diagnosing, monitoring, and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry employing an internal standard, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease. | 10-17-2013 |